Genmab — April 2024

[E_L]

Teknisk: Det endelige positive brud lader vente på sig for Genmab https://ugebrev.dk/flashnews/teknisk-det-endelige-positive-brud-lader-vente-paa-sig-for-genmab/ - i draw my lines a bit different, but it is an opinion..

[E_L]

Goldman Sachs sänker riktkursen för Genmab till 2 218 danska kronor (2 284), upprepar neutral - BN (Finwire)
2024-04-25 06:30 https://www.placera.se/placera/telegram/2024/04/25/genmab-goldman-sachs-sanker-riktkursen-for-genmab-till-2-218-danska-kronor-2-284-upprepar-neutral-bn.html

[E_L]

Sanofi Sarclisa Q1 '24 €106mn https://ml-eu.globenewswire.com/Resource/Download/ca345f70-58d6-4aa7-a4b1-8b6b43551051

[E_L]

Keytruda sales
$

6,947 . for 1 quarter...

[Solsen]

Spectacular !

[E_L]

this may be useful for future
Congress Presentations - hint you are a US healthcare professional https://www.genmabmedicalaffairs.com/congress

[E_L]

new trial - A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/​Metastatic Head and Neck Cancer (OrigAMI-4) https://clinicaltrials.gov/study/NCT06385080

[ProinvestorNEWS]

Kort video..Der er kommet Q1-regnskab fra flere amerikanske selskaber. Bl.a. Tesla, IBM og Meta. Fedmeaktierne Novo Nordisk, Eli Lilly og Zealand Pharma falder efter kritik i USA af prissætningen på fedmeprodukter. Genmab falder også, efter to banker sænker kursmålet. https://www.proinvestor.com/boards/120115/

[Sukkeralf]

Regarding GEN1046 at ASCO - not impressed if its only a poster.

[E_L]

i was thinking the same to be honest...

[LP90]

Aktien har det godt nok svær

[LP90]

Godmorgen det gode ved aktien er faldet så meget er at den jo så også kan stige meget

[w]

jo længere ned den kommer,
jo flere aktier kan ledelsen ta' ud af markedet

[w]

Jeg faldt over Roei Mazor's kommentar på linkedin i forbindelse med FDA's mrd beslutning og hvad det kunne medføre for hexCD38: "Fascinating to see this asset in action".

[w]

tester han stoffet på sin klinik?

[JKY_VH]

Pas, men et eller andet har han jo tydeligvis set.

[E_L]

Roche Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn

[E_L]

AbbVie Epkinly US $12, Intern. $15, Total $27. Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain
international territories

[E_L]

https://investors.abbvie.com/static-files/af510304-0bc1-4781-9090-b6c4a9be5edb

[E_L]

it's a bit difficult to get the exact total sales # out of this, i assume x2 for now. (Last year full 2023 Abbvie reported full year $31mn versus Genmab $64)